CDLX
Cardlytics Inc
Cardlytics Inc historical holders
total: 3
CAS Investment Partners Cardlytics Inc transactions over time
- Total transactions:
- 16
- New positions:
- 1
- Added:
- 11
- Reduced:
- 4
- Held since:
- 2019 Q2
- Held for:
- 28 quarters
- Latest activity:
- 2025 Q3
Clifford Sosin has been an institutional investor in Cardlytics Inc (CDLX) since 2019 Q2. According to 2026 Q1 report, Clifford Sosin holds 519,807 shares with a market value of roughly $5.46M representing 0.31% of their equity portfolio. The fund/company first acquired CDLX in 2019 Q2, initially purchasing 216,202 shares. Since the initial investment, CAS Investment Partners has made 15 more transactions in this position.
Does Clifford Sosin still hold CDLX?
Yes, Clifford Sosin continues to hold Cardlytics Inc (CDLX). According to their 2026 Q1 report, they maintain a position of 519,807 shares valued at approximately $5.46M, representing 0.31% of their equity portfolio.
When did Clifford Sosin first invest in CDLX?
Clifford Sosin first invested in Cardlytics Inc (CDLX) in 2019 Q2 at the reported quarter-end price of $259.80 per share, acquiring 216,202 shares in their initial purchase.
What is Clifford Sosin's average cost basis for CDLX?
Based on historical transaction data, Clifford Sosin's estimated cost basis for Cardlytics Inc (CDLX) is approximately $406.16 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $406.16
- Weighted AVG sell price:
- $21.45
CDLX transactions history by CAS Investment Partners
16 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.56%
|
519,806.7
|
$24.30
|
$12,631,303
|
-7.41% (-41,585.5)
|
-0.05%
|
|
2025 Q1
|
0.66%
|
561,392.2
|
$18.20
|
$10,217,338
|
-11.85% (-75,498.8)
|
-0.08%
|
|
2024 Q4
|
1.38%
|
636,891
|
$37.10
|
$23,628,656
|
-0.79% (-5,082.3)
|
-0.01%
|
|
2024 Q3
|
1.36%
|
641,973.3
|
$32.00
|
$20,543,146
|
-0.70% (-4,512.6)
|
-0.01%
|
|
2024 Q2
|
4.15%
|
646,485.9
|
$82.10
|
$53,076,492
|
+1.43% (+9,118.3)
|
+0.06%
|
|
2024 Q1
|
8.28%
|
637,367.6
|
$144.90
|
$92,354,565
|
+17.68% (+95,756)
|
+1.24%
|
|
2022 Q1
|
19.93%
|
541,611.6
|
$549.80
|
$297,778,000
|
+4.43% (+22,965)
|
+0.85%
|
|
2021 Q4
|
17.89%
|
518,646.6
|
$660.90
|
$342,774,000
|
+0.72% (+3,687.5)
|
+0.13%
|
|
2021 Q3
|
20.60%
|
514,959.1
|
$839.40
|
$432,257,000
|
+14.72% (+66,061.9)
|
+2.64%
|
|
2020 Q4
|
35.51%
|
$1,427.70
|
+2.22% (+9,738.6)
|
|||
|
2020 Q3
|
21.48%
|
$705.70
|
+9.40% (+37,733.7)
|
|||
|
2020 Q2
|
30.25%
|
$699.80
|
+1.59% (+6,273.4)
|
|||
|
2020 Q1
|
30.38%
|
$349.60
|
+40.04% (+112,980.5)
|
|||
|
2019 Q4
|
29.17%
|
$628.60
|
+21.66% (+50,229.9)
|
|||
|
2019 Q3
|
17.17%
|
$335.20
|
+7.28% (+15,739.1)
|
|||
|
2019 Q2
|
14.39%
|
$259.80
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.